The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Mood and anxiety
Does it help anxiety or low mood?
Measured on rating scales, in people who mostly had a diagnosis.
1,732 people · 16 human studies · 14 compounds
- 1,432 people1 study
CHOIR: 1,432 people with chronic kidney disease randomised open-label to a haemoglobin target of 13.5 or 11.3 g/dL, median 16 months. The composite of death, myocardial infarction, heart failure hospitalisation and stroke occurred 125 times in the high-target group and 97 times in the low-target group, hazard ratio...
New England Journal of Medicine, 2006 · 1,432 people
- 62 people1 study
62 patients with generalised anxiety disorder or neurasthenia randomised to Selank, 30 patients, or the benzodiazepine medazepam, 32 patients. Anxiolytic effects were similar between the two, and Selank additionally showed anti-asthenic and psychostimulant effects. An active comparator design with no placebo arm, and...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 62 people1 study
62 patients with generalised anxiety disorder and neurasthenia, 30 on selank and 32 on medazepam, assessed with the Hamilton, Zung and CGI scales alongside serum enkephalin activity. The anxiolytic effects of the two drugs were similar, and selank also showed antiasthenic and psychostimulant effects. An active...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 62 people1 study
62 patients with generalised anxiety disorder and neurasthenia, 30 on selank against 32 on medazepam. Anxiolytic effects were similar between the two drugs, and selank additionally showed antiasthenic and psychostimulant effects. The psychostimulant finding is worth noting in a product sold for sleep.
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 39 people1 study
39 adults with functional constipation, four weeks of 12 g chicory inulin daily in a double-blind placebo-controlled crossover. Stool frequency, abdominal symptoms and constipation-related quality of life improved relative to placebo, alongside higher relative abundance of butyrate-producing Anaerostipes and...
BMC Gastroenterology, 2025 · 39 people
- 29 people1 study
Kisspeptin-54, not kisspeptin-10. In 29 healthy men, kisspeptin-54 enhanced limbic responses to sexual and couple-bonding images and reduced negative mood versus vehicle.
Journal of Clinical Investigation, 2017 · 29 people
- 26 people1 study
Live bee stings, up to 20 per session three times weekly for 24 weeks, versus no treatment, in 26 people with relapsing MS. No reduction in new gadolinium enhancing MRI lesions, T2 lesion load, relapse rate, disability, fatigue or quality of life. No serious adverse events. Academic trial, Netherlands.
Neurology, 2005 · 26 people
- 20 people1 study1 found nothing
found nothingThe only trial of NPY itself in people resolved here. Twenty six individuals with PTSD were randomised into one of five single ascending dose cohorts of intranasal NPY, from 1.4 mg to 9.6 mg, each dosed with NPY and with placebo a week apart under double-blind crossover conditions, with assessment after a trauma...
International Journal of Neuropsychopharmacology, 2018 · 20 people
- no headcount stated3 studies
Phase 3, 465 enrolled, weekly intravenous rapastinel 450 mg or placebo added to an antidepressant. Posted results: MADRS change at 3 weeks of -4.7 on rapastinel versus -5.0 on placebo, least squares mean difference 0.3 (95% CI -1.07 to 1.72), p = 0.65. Sponsor funded; results posted October 2019, never published in a...
ClinicalTrials.gov, Naurex / Allergan, 2016 · no headcount in the line
Phase 3, 658 enrolled, rapastinel 225 mg, 450 mg or placebo weekly. Posted results: MADRS change at 3 weeks of -4.8 (225 mg), -5.4 (450 mg) and -4.9 (placebo); p = 0.89 for 225 mg versus placebo and p = 0.58 for the 450 mg comparison. Sponsor funded; results posted December 2019.
ClinicalTrials.gov, Naurex / Allergan, 2016 · no headcount in the line
Phase 3, 429 enrolled, rapastinel 450 mg or placebo weekly. Posted results: MADRS change at 3 weeks of -5.1 versus -4.1, least squares mean difference -1.0 (95% CI -2.70 to 0.68), p = 0.24. Sponsor funded; results posted November 2019.
ClinicalTrials.gov, Naurex / Allergan, 2016 · no headcount in the line
- no headcount stated1 study
81 outpatients with major depression randomised to 30 mg/day, 45 mg/day or placebo by subcutaneous injection on weekdays for 2 weeks, followed for 4 more. Primary measure MADRS change. The authors report superiority of 45 mg over placebo at the timepoint of peak effect, one week after treatment ended, and separation...
International Journal of Neuropsychopharmacology, 2006 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingThe T-Trials. Treatment raised testosterone into the mid-normal range for men aged 19 to 40. Sexual activity, sexual desire and erectile function all improved significantly. Vitality did not improve on the fatigue scale. The proportion improving 6-minute walking distance by at least 50 m did not differ in the Physical...
New England Journal of Medicine, 2016 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingONTRANS, the replication attempt by the same group in a higher-risk population. 158 organ-transplant recipients with at least two keratinocyte cancers in the previous 5 years, randomised 1:1 to the same 500 mg twice daily for 12 months. The trial was stopped early for poor recruitment. There were 207 new keratinocyte...
New England Journal of Medicine, 2023 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingA clean randomised controlled negative on a behavioural endpoint. Kisspeptin administration raised reproductive hormones as expected and did not affect anxiety. This is the closest the kisspeptin literature comes to a psychological outcome measure, and the result was null.
The Journal of Clinical Endocrinology and Metabolism, 2025 · no headcount in the line
- no headcount stated1 study
Thirty pre- and postmenopausal women with sexual dysfunction, randomised double-blind placebo-controlled crossover over 22 weeks, 32 IU of intranasal oxytocin or placebo before intercourse. Female Sexual Function Index rose 26% on oxytocin and 31% on placebo, Sexual Quality of Life 144% and 125%, and sexual distress...
Fertility and Sterility, 2015 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.